Immunomodulation by IAP inhibitors
AssigneesDana-Farber Cancer Institute, Inc., Novartis AG
InventorsLeigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
Life of this patent
Estimating the term…
Abstract
The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
Claims19
A method of enhancing an immune response of a subject with melanoma, said method comprising administering to the subject an immune enhancing amount of an IAP inhibitor, wherein the IAP inhibitor is:
- (S)—N—((S)-1-Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;
- or a pharmaceutically acceptable salt thereof, wherein the administration of the immune enhancing amount of the IAP inhibitor potentiates cytokine production.
A method of enhancing an immune response of a subject with melanoma to an antigen, comprising (a) administering to the subject an immunogenic quantity of an antigen, the antigen being a tumor antigen;
- and (b) administering an immune enhancing amount of an IAP inhibitor selected from the group consisting of:
- (S)—N—((S)-1-Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide
- or a pharmaceutically acceptable salt thereof.
A method of treating a cancer in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of an IAP inhibitor selected from the group consisting of:
- (S)—N—((S)-1-Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;
- or a pharmaceutically acceptable salt thereof, and an immunogenic quantity of an antigen, the antigen being a tumor antigen, wherein administration of said IAP inhibitor and said tumor antigen enhances the immune response of the subject to the cancer, and the cancer is melanoma.
Dependencies are inferred from the claim text.